

A. BASIC IDENTIFICATION DATA

2. Enter the information requested for the following:

- X Each promoter of the issuer, if the issuer has been organized within the past five years;
- X Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- X Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
- X Each general and managing partner of partnership issuers.

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)

Bier, Colin B.

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Boston Life Sciences, Inc., 20 Newbury Street, 5th Floor, Boston, MA 02116

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)

Hernon, Joseph P.

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Boston Life Sciences, Inc., 20 Newbury Street, 5th Floor, Boston, MA 02116

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)

Hillson, S. David

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Boston Life Sciences, Inc., 20 Newbury Street, 5th Floor, Boston, MA 02116

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)

Langer, Robert

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Boston Life Sciences, Inc., 20 Newbury Street, 5th Floor, Boston, MA 02116

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)

Lanser, Marc E.

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Boston Life Sciences, Inc., 20 Newbury Street, 5th Floor, Boston, MA 02116

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)

Peck, Steven

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Boston Life Sciences, Inc., 20 Newbury Street, 5th Floor, Boston, MA 02116

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)

Palmer, E. Christopher

Business or Residence Address (Number and Street, City, State, Zip Code)

c/o Boston Life Sciences, Inc., 20 Newbury Street, 5th Floor, Boston, MA 02116

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

B. INFORMATION ABOUT OFFERING

1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering? Yes No

Answer also in Appendix, Column 2, if filing under ULOE.

2. What is the minimum investment that will be accepted from any individual? \$ N/A

3. Does the offering permit joint ownership of a single unit? Yes No

4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.

Full Name (Last name first, if individual)

Burnham Hill Partners (a division of Pali Capital, Inc.)

Business or Residence Address (Number and Street, City, State, Zip Code)

570 Lexington Avenue, New York, NY 10022

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) All States

[AL] [AK] [AZ] [AR] X[CA] X[CO] X[CT] X[DE] [DC] X[FL] X[GA] [HI] [ID]
X[IL] X[IN] [IA] [KS] [KY] [LA] [ME] X[MD] X[MA] X[MI] X[MN] [MS] [MO]
[MT] [NE] X[NV] [NH] X[NJ] [NM] X[NY] [NC] [ND] [OH] X[OK] X[OR] X[PA]
[RI] X[SC] [SD] [TN] [TX] X[UT] [VT] [VA] [WA] [WV] [WI] [WY] [PR]

Full Name (Last name first, if individual)

Viewtrade Financial

Business or Residence Address (Number and Street, City, State, Zip Code)

7280 W. Palmetto Park Road, Suite 105, Boca Raton, FL 33433

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) All States

[AL] [AK] [AZ] [AR] X[CA] [CO] [CT] [DE] [DC] X[FL] [GA] [HI] [ID]
X[IL] [IN] [IA] [KS] [KY] [LA] [ME] [MD] X[MA] X[MI] X[MN] [MS] [MO]
[MT] [NE] X[NV] [NH] X[NJ] [NM] X[NY] [NC] [ND] [OH] X[OK] X[OR] X[PA]
[RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI] [WY] [PR]

Full Name (Last name first, if individual)

Kimball & Cross Investment Management Corp.

Business or Residence Address (Number and Street, City, State, Zip Code)

50 Congress Street, Suite 721, Boston, MA 02109

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) All States

[AL] [AK] [AZ] [AR] X[CA] [CO] [CT] X[DE] [DC] X[FL] X[GA] [HI] [ID]
[IL] X[IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS] [MO]
[MT] [NE] X[NV] X[NH] X[NJ] [NM] [NY] [NC] [ND] [OH] [OK] [OR] [PA]
[RI] X[SC] [SD] [TN] [TX] [UT] [VT] X[VA] [WA] [WV] [WI] [WY] [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.

| Type of Security | Aggregate Offering Price | Amount Already Sold |
|--|--------------------------|---------------------|
| Debt | \$ | \$ |
| Equity | \$ | \$ |
| <input type="checkbox"/> Common <input type="checkbox"/> Preferred | | |
| Convertible Securities (including warrants) | \$ 8,000,000 | \$ 8,000,000 |
| Partnership Interests | \$ | \$ |
| Other (Specify _____) | \$ | \$ |
| Total | \$ 8,000,000 | \$ 8,000,000 |

Answer also in Appendix, Column 3, if filing under ULOE.

2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."

| | Number Investors | Aggregate Dollar Amount of Purchases |
|--|------------------|--------------------------------------|
| Accredited Investors..... | 89 | \$ 8,000,000 |
| Non-accredited Investors..... | | \$ |
| Total (for filings under Rule 504 only)..... | | \$ |

Answer also in Appendix, Column 4, if filing under ULOE.

3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.

| Type of offering | Type of Security | Dollar Amount Sold |
|--------------------|------------------|--------------------|
| Rule 505..... | | \$ |
| Regulation A | | \$ |
| Rule 504..... | | \$ |
| Total | | \$ |

4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.

| | | |
|---|-------------------------------------|------------|
| Transfer Agent's Fees | <input type="checkbox"/> | \$ |
| Printing and Engraving Costs | <input type="checkbox"/> | \$ |
| Legal Fees | <input checked="" type="checkbox"/> | \$ 190,000 |
| Accounting Fees..... | <input type="checkbox"/> | \$ |
| Engineering Fees..... | <input type="checkbox"/> | \$ |
| Sales Commissions (specify finders' fees separately)..... | <input checked="" type="checkbox"/> | \$ 584,700 |
| Other Expenses (identify) | <input type="checkbox"/> | \$ |
| Total..... | <input checked="" type="checkbox"/> | \$ 774,700 |

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

4. b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer."


\$ 7,225,300

5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b. above.

| | Payments to Officers, Directors, & Affiliates | Payments To Others |
|---|---|--|
| Salaries and fees..... | <input type="checkbox"/> \$ | <input type="checkbox"/> \$ |
| Purchase of real estate..... | <input type="checkbox"/> \$ | <input type="checkbox"/> \$ |
| Purchase, rental or leasing and installation of machinery and equipment..... | <input type="checkbox"/> \$ | <input type="checkbox"/> \$ |
| Construction or leasing of plant buildings and facilities..... | <input type="checkbox"/> \$ | <input type="checkbox"/> \$ |
| Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)..... | <input type="checkbox"/> \$ | <input type="checkbox"/> \$ |
| Repayment of indebtedness..... | <input type="checkbox"/> \$ | <input type="checkbox"/> \$ |
| Working capital..... | <input type="checkbox"/> \$ | <input checked="" type="checkbox"/> \$ 7,225,300 |
| Other (specify): | <input type="checkbox"/> \$ | <input type="checkbox"/> \$ |
| Column Totals..... | <input type="checkbox"/> \$ | <input checked="" type="checkbox"/> \$ 7,225,300 |
| Total Payments Listed (column totals added)..... | <input checked="" type="checkbox"/> \$ 7,225,300 | |

D. FEDERAL SIGNATURE

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

| | | |
|---|--|----------------------------------|
| Issuer (Print or Type) Boston Life Sciences, Inc. | Signature  | Date December 23, 2003 |
| Name of Signer (Print or Type) Joseph P. Hernon | Title of Signer (Print or Type) Executive Vice President, Chief Financial Officer, and Secretary | |

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

ATTENTION